ViewRay Shares Rise

ViewRay shares rose 6% on Monday after the company said it presented “compelling early pancreatic cancer data” on its MRIdian radiation therapy system. The company said early results illustrated MRIdian’s ability to “deliver high doses with low toxicity, despite the proximity of the duodenum, through the use of daily plan adaptation and real-time tracking.”

The company said that based on these data, it plans to support a multi-institutional single-arm prospective clinical trial in unresectable pancreatic cancer to demonstrate the benefits of MRIdian’s daily on-table adaptive Stereotactic Body Radiation Therapy and real-time tissue tracking capabilities, with a focus on toxicity, local control and overall survival outcomes.

Leave a Comment